Trial record 1 of 98 for:    renal af
Previous Study | Return to List | Next Study

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation (RENAL-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02942407
Recruitment Status : Recruiting
First Posted : October 24, 2016
Last Update Posted : July 27, 2017
Bristol-Myers Squibb
Information provided by (Responsible Party):
Christopher Granger, Duke University

Brief Summary:
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .

Condition or disease Intervention/treatment Phase
Atrial Fibrillation End Stage Renal Disease Drug: apixaban Drug: warfarin Phase 4

Detailed Description:
This is a multicenter study in adult patients with AF and ESRD who are on hemodialysis and who have stroke risk factors making them candidates for oral anticoagulation. Patients will be randomized to apixaban versus warfarin, and will be treated for up to 15 months.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 762 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Study Start Date : December 2016
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: apixaban
apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
Drug: apixaban
oral anticoagulant
Other Name: Eliquis

Experimental: warfarin
warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
Drug: warfarin
oral anticoagulant
Other Names:
  • Coumadin
  • Jantoven

Primary Outcome Measures :
  1. Time (measured in days) from randomization to the onset of first major bleeding/clinically relevant non-major bleeding event, as described by International Society of Thrombosis and Haemostasis (ISTH) [ Time Frame: 15 months ]

Secondary Outcome Measures :
  1. stroke or systemic embolism [ Time Frame: 15 months ]
  2. mortality [ Time Frame: 15 months ]
    all-cause death

  3. adherence to treatment with apixaban or with warfarin, measured by pill count for patients randomized to apixaban, and by time in therapeutic range (TTR) for warfarin [ Time Frame: 15 months ]
    including discontinuation for adverse events

  4. apixaban plasma concentration. [ Time Frame: Baseline: Day 3, 4, or 5; Day 28 ]
    Pharmacokinetics; only in the apixaban treated patients

  5. plasma apixaban concentration, Cmax [ Time Frame: Baseline: Day 3, 4, or 5; Day 28 ]

  6. plasma apixaban concentration, Cmin [ Time Frame: Baseline: Day 3, 4, or 5; Day 28 ]

  7. plasma apixaban concentration, area under the curve (AUC) [ Time Frame: Baseline: Day 3, 4, or 5; Day 28 ]

  8. apixaban pharmacodynamics, chromogenic factor Xa assay [ Time Frame: Baseline: Day 3, 4, or 5; Day 28 ]

Other Outcome Measures:
  1. baseline biomarkers to assess for prediction of clinical outcomes such as bleeding. Biomarkers to be assessed are Growth/differentiation factor 15(GDF-15), high sensitivity troponin T (hs-trop T), B-type natriuretic peptide (NT-proBNP). [ Time Frame: Baseline ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, age at least 18 years, or the local age of consent, whichever is greater.
  • Patients with AF defined as AF on ECG at enrollment or two or more reports of AF from separate monitoring events at least 2 weeks apart (report of ECG, Holter monitor, event monitor or implantable loop recorder).
  • CHA2DS2-VASc score of ≥ 2.
  • End-stage renal disease treated with hemodialysis for ≥ 3 months.
  • Considered by the treating physician(s) to be candidate for oral anticoagulation.
  • If of childbearing potential, be willing to avoid pregnancy during the study.

Exclusion Criteria:

  • Not considered by the treating physician(s) to be candidates for oral anticoagulation (for example, hemoglobin < 8.5g/dL, history of intracranial hemorrhage, active bleeding, recent gastrointestinal bleed or retroperitoneal bleed, severe hepatic impairment, or anaphylactic reaction to apixaban)
  • Moderate or severe mitral stenosis
  • Conditions other than AF that require anticoagulation such as mechanical prosthetic valve, deep venous thrombosis, or pulmonary embolism
  • Need for aspirin at a dose > 81 mg a day or need for P2Y12 antagonist therapy (for example clopidogrel, prasugrel, or ticagrelor)
  • Life expectancy < 3 months
  • Anticipated kidney transplant within the next 3 months
  • Prisoners or others who are involuntarily incarcerated or detained
  • Pregnant, breastfeeding, or considering pregnancy.
  • Participation in a clinical trial of an experimental treatment within the past 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02942407

Contact: Pat Dignacco, BSMT 919-668-8482

United States, Florida
Genesis Clinical Research Not yet recruiting
Tampa, Florida, United States, 33614
Contact: Eric Berrios   
United States, Idaho
Boise Kidney and Hypertension Institute Recruiting
Meridian, Idaho, United States, 83642
Contact: Eric Berrios   
United States, Massachusetts
South Shore Nephrology Not yet recruiting
Plymouth, Massachusetts, United States, 02360
Contact: Eric Berrios   
United States, Michigan
Paragon Health Neprhology Centre Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Eric Berrios   
United States, Mississippi
Nephrology & Hypertension Associates Not yet recruiting
Tupelo, Mississippi, United States, 38801
Contact: Eric Berrios   
United States, Missouri
Metro Hypertension & Kidney Center Recruiting
Saint Louis, Missouri, United States, 63136
Contact: Eric Berrios   
United States, North Carolina
Durham Nephrology Associates Not yet recruiting
Durham, North Carolina, United States, 27704
Contact: Eric Berrios   
United States, Pennsylvania
Northeast Clinical Research Ctr Recruiting
Bethlehem, Pennsylvania, United States, 18017
Contact: Eric Berrios   
United States, Tennessee
Knoxville Kidney Center Recruiting
Knoxville, Tennessee, United States, 37923
Contact: Eric Berrios   
Sponsors and Collaborators
Christopher Granger
Bristol-Myers Squibb
Principal Investigator: Christopher Granger, MD Duke University
Principal Investigator: Glenn Chertow, MD Stanford University

Additional Information:

Responsible Party: Christopher Granger, Professor of Medicine, Duke University Identifier: NCT02942407     History of Changes
Other Study ID Numbers: Pro00068545
First Posted: October 24, 2016    Key Record Dates
Last Update Posted: July 27, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Keywords provided by Christopher Granger, Duke University:
Renal dialysis

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Urologic Diseases
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action